Login / Signup

Impact of dipyridamole on adenosine dosing in pediatric and young adult patients after heart transplantation.

Michael B SatzerJonathan N FlyerWarren A ZuckermanLeonardo LibermanMarc E RichmondBrett R AndersonLinda J AddonizioEric S Silver
Published in: Pediatric transplantation (2020)
AV block often occurs at twofold lower adenosine doses in healthy young heart transplant recipients taking oral dipyridamole, compared with previous testing of this cohort off dipyridamole. Results suggest that initial dosing of 25 mcg/kg (maximum 0.8 mg) with stepwise escalation poses low risk of prolonged asystole on dipyridamole.
Keyphrases
  • middle aged
  • heart failure
  • protein kinase
  • atrial fibrillation
  • randomized controlled trial
  • clinical trial
  • young adults
  • study protocol